Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease

British Journal of Cancer

Volumn 75, Issue 5, 1997, Pages 698-702

  Tampellini, M ^a   Berruti, A ^a   Gerbino, A ^a   Buniva, T ^a   Torta, M ^a   Gorzegno, G ^a   Faggiuolo, R ^a   Cannone, R ^a   Farris, A ^b   Destefanis, M ^c   Moro, G ^d   Deltetto, F ^e   Dogliotti, L ^a,f  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c Ospedale Civile di Alba   (Italy)

^d Ospedale Civile   (Italy)

^e MAURIZIANO HOSPITAL   (Italy)

^f SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Breast cancer; CA 15 3; Disease extent; Survival

Indexed keywords

AMINOGLUTETHIMIDE; CA 15-3 ANTIGEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; LONIDAMINE; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE SEVERITY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; PLEURA EFFUSION; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 8044245945     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.124     Document Type: Article

References (28)

1. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G and Dogliotti L (1994) Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 30A: 2082-2084
2. Bombardieri E, Pizzichetta M, Veronesi P, Seregni E, Bogni A, Maffioli L, Saccani Jotti G, Bassetto MA, Zurrida S and Costa A (1993) CA 15-3 determination in patients with breast cancer: clinical utility for the detection of distant metastases. Eur J Cancer 29A: 144-146
3. Chlebowski RT and Lillington LM (1994) A decade of breast cancer clinical investigation: results as reported in the program/proceedings of the American society of clinical oncology. J Clin Oncol 12: 1789-1795
4. Clark GM, Sledge GW, Osborne CK and Mc Guire WL (1987) Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 5: 55-61
5. Clavel M and Catimel G (1993) Breast cancer: chemotherapy in the treatment of advanced disease. Eur J Cancer 29A: 598-604
6. Colomer R, Ruibal A and Salvador L (1989) Circulating tumour marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64: 1674-1681
7. de Wit R, Hoek FJ, Bakker PJ and Veenhof CH (1992) A comparison of CA-549 with CA 15-3 and MCA in patients with metastatic breast cancer. Ann Oncol 3. 314-315
8. Dogliotti L, Faggiuolo R, Buniva T, Berruti A, Torta M and Tampellini M (1990) Serum CA 15-3 evaluation in breast cancer. J Nucl Med All Sci 34 (suppl.): 211-216
9. Dogliotti L, Berruti A, Buniva T, Zola P, Baü MG, Farris A, Sarobba MG, Bottini A, Arquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M and Perroni D (1996) Lonidamine significantly increases the activity of epirubicin in advanced breast cancer patients. Results from a multicenter prospective randomized trial. J Clin Oncol 14: 1165-1172
10. Geraghty JG, Coveney EC, Sherry F, O'Higgins and Duffy MJ (1992) CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 70: 2831-2834
11. Gion M, Cappelli G, Mione R, Pistorello M, Meo S, Vignati G, Fortunato A, Saracchini S, Biasoli R and Giulisano M (1994) Evaluation of critical differences of CEA and CA 15-3 levels in serial samples from patients operated for breast cancer. Int J Biol Markers 9: 135-139
12. Gourevitch MM, Von Mensdorff-Pouilly S, Litvinov SV, Kenemans P, Van Kamp GJ, Verstraeten AA and Hilgers J (1995) Polymorphic epithelial mucin (MUCI)-containing circulating immune complexes in carcinoma patients. Br J Cancer 72: 934-938
13. Gregory WM, Smith P, Richards MA, Twelves CJ, Knight RK and Rubens RD (1993) Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer 68: 988-995
14. Hayes DF (1993) Tumor markers for breast cancer. Ann Oncol 4: 807-819
15. Hayes DF, Henderson C and Shapiro C (1995) Treatment of metastatic breast cancer: present and future prospects. Semin Oncol 22: 5-21
16. Henson DE, Ries L, Freedman LS and Carriaga M (1991) Relationship among outcome, stage of disease, and histological grade for 22,616 cases of breast cancer. Cancer 68: 2142-2149
17. Koenders PG, Beex LV, Kloppenborg PW, Smals AG and Benraad TJ (1992) Human breast cancer: survival from first metastasis. Breast Cancer Res Treat 21: 173-180
18. La Vecchia C, Negri E, Decarli A, Fasuli M and Cislaghi C (1990) Cancer mortality in Italy: an overview of age-specific and age-standardized trends from 1955 to 1984. Tumori 76: 87-166
19. Nie NH, Hull CH and Jeakins JG (1988) Statistical Package for the Social Sciences SPSS: Chicago
20. Overmoyer BA (1995) Chemotherapeutic palliative approaches in the treatment of breast cancer. Semin Oncol 22: 2-9
21. Robertson JFR, Pearson D, Price MR, Selby C, Blamey RW and Howell A (1991) Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer 64: 757-763
22. Saccuni Jotti G and Bombardieri E (1990) Circulating tumor markers in breast cancer. Anticancer Res 10: 253-258
23. Safi F, Kohler I, Rottinger E, Suhr P and Beger HG (1989) Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 4: 207-214
24. Solétormos G, Nielsen D, Schioler V, Skovsgaard T, Winkel P, Mouridsen HT and Dombernowsky P (1993) A novel method for monitoring high-risk breast cancer with tumour markers: CA 15-3 compared to CEA and TPA. Ann Oncol 4: 861-869
25. Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap Hwee-Y, Gutterman JU and Blumenschein GR (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39: 1552-1562
26. Tondini C, Hayes DF, Gelman R, Henderson C and Kufe DW (1988) Comparison of CA 15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48: 4107-4112
27. Yadav GC, Rao A, Motawy MM, Safadi N and Ahmed MJ (1993) CA 15-3 with urinary calcium excretion is useful in the diagnosis and monitoring of bone metastases from breast cancer. Int J Biol Markers 8: 208-214
28. Zinser JW, Hortobagyi GN, Buzdar AU, Smith T and Fraschini G (1987) Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5: 773-782